Multi-Microcoil Probes for Capillary NMR Detection

用于毛细管 NMR 检测的多微线圈探针

• 批准号: 7294781
• 负责人: TIMOTHY L PECK
• 金额: $ 9.28万
• 依托单位: PROTASIS CORPORATION
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7294781
• 关键词: Multi; Microcoil; Probes; Capillary; NMR

DESCRIPTION (provided by applicant): The overall goal of this SBIR effort is to commercialize a new family of capillary-scale, high-resolution nuclear magnetic resonance (NMR) spectroscopy flowprobes that employ multiple detection cells in a single probe for high throughput. NMR is utilized extensively by the pharmaceutical and biotechnology industries, but remains one of few analytical methods in which parallel data acquisition has not been applied to increase the number of samples that can be simultaneously evaluated. The reasons behind this are the intrinsically related to the hardware involved in data acquisition. Poor throughput (i.e. relatively long time required for NMR analysis) remains a formidable challenge in drug discovery and development. The company submitting this proposal has a demonstrated track record of using SBIR funding to commercialize novel microcoil (capillary-based) NMR probe technologies. This proposal builds upon the speed and throughput advantages that have been achieved in capillary scale NMR to further advance high throughput screening through multi-sample analysis using a single probe. Technical aspects of both probe design and sample management is addressed. The long-term implications of this technological advance to health and health-related companies, particularly pharmaceutical companies, are significant. The ability to coordinate sample entry, sample exit, and NMR data acquisition for multiple samples in a single magnet/spectrometer/probe system pushes the boundaries of NMR and holds potential to dramatically change the way in which NMR is performed in the future.

描述（由申请人提供）： 这项SBIR工作的总体目标是商业化一个新的毛细管规模，高分辨率核磁共振（NMR）光谱流动探针，采用多个检测单元在一个单一的探针高通量的家庭。 NMR被制药和生物技术行业广泛使用，但仍然是为数不多的分析方法之一，其中并行数据采集尚未应用于增加可以同时评估的样品数量。这背后的原因与数据采集中涉及的硬件有着内在的联系。低通量（即NMR分析所需的相对长的时间）仍然是药物发现和开发中的巨大挑战。提交该提案的公司在使用SBIR资金将新型微线圈（基于毛细管）NMR探针技术商业化方面有着良好的记录。该提议建立在毛细管级NMR中已经实现的速度和通量优势的基础上，以通过使用单个探针的多样品分析来进一步推进高通量筛选。探头设计和样品管理的技术方面得到解决。这一技术进步对健康和与健康有关的公司，特别是制药公司的长期影响是巨大的。在单个磁体/光谱仪/探针系统中协调多个样品的样品进入、样品退出和NMR数据采集的能力推动了NMR的边界，并有可能极大地改变未来NMR的执行方式。